What DSM-Firmenich's Final Investor Day Tells Us About the Future of Animal Nutrition

DSM-Firmenich's €2.2 billion sale of its animal nutrition business to CVC Capital Partners marks the final act in a two-year portfolio transformation.

It also creates a critical ownership split that every institutional investor in production animal protein needs to understand.

Bovaer, the methane-reducing feed additive with a stated revenue target above €200 million, stays with DSM-Firmenich. Everything else goes to CVC: vitamins, premixes, performance solutions, carotenoids.

Following a DSM investor day we take some time to do a bit of a retrospective…

DSM-Firmenich initially targeted roughly €3 billion for its Animal Nutrition & Health unit. It got €2.2 billion, including an earn-out of up to €500 million that may never fully materialize. That implies roughly 7x normalized EBITDA on a standalone basis.

Apollo Global Management withdrew from bidding, leaving CVC as the sole credible buyer and stripping competitive tension from the process. The €1.9 billion non-cash impairment DSM-Firmenich booked in 2025 quietly acknowledged the gap between book value and market reality.

Shares fell roughly 4% on announcement day. They dropped another 8% when full-year results landed three days later without 2026 guidance.

Combined with the prior €1.5 billion Feed Enzymes sale to Novonesis (closed June 2025), total ANH proceeds reach €3.7 billion at roughly 10x blended EBITDA. More respectable, but still below what a consolidated sale might have achieved in a friendlier vitamin pricing environment.

The structural headwind is familiar to this audience. Chinese overcapacity, with over 73% of global vitamin production concentrated in mainland facilities, continues to compress margins across the commodity ingredients base. DSM-Firmenich's ANH revenue had already declined 15% to €3.4 billion in 2023 for precisely this reason.

CVC is splitting ANH into two standalone Swiss-headquartered companies. A Solutions Company (premixes, precision services, performance solutions) and an Essential Products Company (vitamins, carotenoids, aroma ingredients).

Separating the higher-margin, innovation-driven business from the capital-intensive commodity operation enables differentiated value creation strategies, independent bolt-on acquisition tracks, and separate exit timing. CVC's recent PE exits have averaged roughly 3.3x invested capital at approximately 27% gross IRR. A €2.2 billion entry implies a target exit valuation of €6 to €7 billion over a five-to-seven-year hold.

The advisory roster confirms the ambition: Rabobank and Morgan Stanley on M&A, Kearney and McKinsey on operations and commercial strategy from day one.

CVC is also building broader animal agriculture exposure. Its 2024 investment in URUS Group, which monitors 14 million cows via cloud-based dairy genetics platforms, signals a thesis-driven approach to the livestock value chain rather than an opportunistic one-off.

DSM-Firmenich's retained 20% equity stake in both entities, plus a €450 million loan facility to the Essential Products Company and a long-term vitamins supply agreement, means it remains structurally committed. The press release states equity value will be realized upon exit. Translated from corporate diplomacy, that points toward a re-IPO or secondary sale in the 2031 to 2033 window.

The most consequential detail in the transaction is what was excluded.

Bovaer was carved out of ANH and reclassified into DSM-Firmenich's Taste, Texture & Health segment as a continuing operation. At the March 12 Investor Event in London, the company presented Bovaer's metrics directly: approximately €40 million in 2025 sales at EBITDA break-even, 500,000-plus cows across 25 countries, regulatory approval in 70 markets, and a dedicated production plant in Dalry, Scotland expected to come online in 2026.

The stated trajectory runs from €40 million to over €200 million in revenue, with commercial contribution beginning in 2027.

The Elanco alliance, expanded from U.S.-only to all of North America in May 2024, remains intact with DSM-Firmenich as the counterparty. Elanco secured FDA enforcement discretion (notably, not formal drug approval) for lactating dairy cattle in May 2024 and launched commercially in Q3 2024. By year-end 2025, more than 150,000 U.S. dairy cows were receiving Bovaer with farmer retention rates above 90%.

Elanco classifies Bovaer among its top innovation products, which collectively generated $892 million in 2025 revenue.

But institutional investors should weigh this trajectory against a material near-term risk.

In Denmark, where a methane-reduction mandate took effect January 2025, approximately 400 of 1,600 farms reported adverse health signs in cattle including diarrhea, fever, and reduced milk yields. That is roughly 25% of participating herds. Norway and Sweden suspended Bovaer trials entirely.

In February 2026, the European Commission mandated EFSA to deliver a new scientific opinion on Bovaer's safety for dairy cows. Findings are due by June 30, 2026.

DSM-Firmenich contends no causal link has been established, pointing to seasonal confounders and the absence of similar reports across 25 other markets. The EFSA outcome is binary: a clean bill of health removes the overhang and de-risks the scale-up. Restrictions could fundamentally impair the €200 million-plus target and delay the production ramp that justifies the Dalry investment.

DSM-Firmenich's departure crystallizes what industry observers have called the "barbell reality" in animal nutrition.

At one end: commodity inputs. Vitamins, basic amino acids, standard premixes. These face structural margin compression from Chinese overcapacity and offer limited pricing power. CVC is betting its operational toolkit can extract returns here that a public company, constrained by quarterly earnings expectations, cannot.

At the other end: sustainability-driven products like Bovaer that command genuine pricing power because they address Scope 3 emissions obligations that CPG companies cannot avoid.